Acologix, Inc.
Quick facts
Phase 3 pipeline
- Nalfurafine HCl 2.5 µg · Dermatology
Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system. - Nalfurafine HCl 5.0 µg · Dermatology / Nephrology
Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Acologix, Inc.
What is Acologix, Inc.'s pipeline?
Acologix, Inc. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Nalfurafine HCl 2.5 µg, Nalfurafine HCl 5.0 µg.
Related
- Sector hub: All tracked pharma companies